Article Text

Download PDFPDF

2022-RA-620-ESGO Querleu-Morrow type A hysterectomy for low-risk early-stage (FIGO 2018 IA2-IB1) cervical cancer: a UK population-based retrospective cohort study
Free
  1. Fong Lien Audrey Kwong,
  2. Anastasios Tranoulis,
  3. Jason Yap,
  4. Ahmed Elattar,
  5. Kavita Singh and
  6. Janos Balega
  1. Gynaecological Oncology, The Pan-Birmingham Gynaecological Cancer Centre, Birmingham, UK

Abstract

Introduction/Background To evaluate the long-term oncological outcomes in women with low-risk early-stage cervical cancer (CC)

Methodology Retrospective population-based study of prospectively collected data, spanning the period 2008–2020. Eligibility criteria were: (1) FIGO 2018 IA2-IB1, (2) squamous cell carcinoma or grade 1–2 adenocarcinoma, (3) absence of lympvovascular invasion (LVSI); (4) depth of invasion < 10 mm; (5) negative conization margins (including repeat cone); (6) negative imaging for nodal or distal metastatic disease. Associated factors, overall (OS) and progression-free (PFS) survival were analysed using the Kaplan-Meier method, Log-rank test and Cox regression. Post-operative complications were assessed via the Clavien-Dindo classification. Census day was April 1st, 2022. Statistical significance was set at p-value < 0.05. The statistical analysis was performed using Stata version 16.1.

Results 35 women fulfilled the criteria for enrolment. The median age at diagnosis was 43 years. FIGO stage was IA2 (75.8%) and IB1 (24.2%). Pelvic lymphadenectomy was performed in 53.4% of the cases. Lymphadenectomy omitted in 16 women with stage IA2 and LVSI-negative post-conization completely excised disease. Residual disease in the post-conization hysterectomy specimen was 1/35 (2.9%). Median follow-up was 83.00 (95% CI 24.00 – 159.00) months. During the follow-up period only one recurrence was observed, which resulted in a cumulative 2-year PFS of 97.1%. Mean PFS was 154.96 (95% CI 147.20 – 162.71) months. No severe (Clavien-Dindo >3) post-operative complications were noted.

Conclusion Our data demonstrated that Type A hysterectomy is safe and effective for selective women with early-stage low-risk CC. This evidence is in line with the recent prospective ConCerv trial. Further studies are warranted to draw firmer conclusions.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.